BioLargo Statistics
Want to see BLGO full AI Analyst Report?
BioLargo (BLGO) Stock Statistics & Valuation Metrics
Total Valuation
BioLargo has a market cap or net worth of $22.74M. The enterprise value is $39.76M.
- Market Cap
- $22.74M
- Enterprise Value
- $39.76M
Share Statistics
BioLargo has 334,661,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 334,661,960
- Owned by Insiders
- 12.65%
- Owned by Institutions
- 0.04%
Financial Efficiency
BioLargo’s return on equity (ROE) is -2.91 and return on invested capital (ROIC) is -294.52%.
- Return on Equity (ROE)
- -2.91
- Return on Assets (ROA)
- -1.42
- Return on Invested Capital (ROIC)
- -294.52%
- Return on Capital Employed (ROCE)
- -4.57
- Revenue Per Employee
- 172.56K
- Profits Per Employee
- -261.78K
- Employee Count
- 45
- Asset Turnover
- 0.93
- Inventory Turnover
- 14.06
Valuation Ratios
The current PE Ratio of BioLargo is -1.50. BioLargo’s PEG ratio is 0.01.
- PE Ratio
- -1.50
- PS Ratio
- 5.57
- PB Ratio
- -11.78
- Price to FCF
- -2.19
- Price to Operating Cash Flow
- -2.11
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, BioLargo had revenue of 7.76M and earned -11.78M in profits. Earnings per share was -0.04.
- Revenue
- 7.76M
- Gross Profit
- 3.41M
- Operating Income
- -14.84M
- Pretax Income
- -15.19M
- Net Income
- -11.78M
- EBITDA
- -14.55M
- Earnings Per Share (EPS)
- -0.04
Cash Flow
In the last 12 months, operating cash flow was -10.32M and capital expenditures -46,000, giving a free cash flow of -10.37M billion.
- Operating Cash Flow
- -10.32M
- Free Cash Flow
- -10.37M
- Free Cash Flow per Share
- -0.03
Dividends & Yields
BioLargo pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -44.35%
- Earnings Yield
- -64.61%
Stock Price Statistics
- Beta
- -0.05
- 52-Week Price Change
- -57.05%
- 50-Day Moving Average
- 0.08
- 200-Day Moving Average
- 0.12
- Relative Strength Index (RSI)
- 44.73
- Average Volume (3m)
- 436.76K
Important Dates
BioLargo upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Nov 18, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
BioLargo as a current ratio of 1.01, with Debt / Equity ratio of 86.91%
- Current Ratio
- 1.01
- Quick Ratio
- 0.95
- Debt to Market Cap
- 0.04
- Net Debt to EBITDA
- 0.03
- Interest Coverage Ratio
- -27.48
Taxes
In the past 12 months, BioLargo has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
BioLargo EV to EBITDA ratio is -1.56, with an EV/FCF ratio of -2.66.
- EV to Sales
- 6.76
- EV to EBITDA
- -1.56
- EV to Free Cash Flow
- -2.66
- EV to Operating Cash Flow
- -2.67
Balance Sheet
BioLargo has $2.19M in cash and marketable securities with $6.39M in debt, giving a net cash position of -$4.21M billion.
- Cash & Marketable Securities
- $2.19M
- Total Debt
- $6.39M
- Net Cash
- -$4.21M
- Net Cash Per Share
- -$0.01
- Tangible Book Value Per Share
- -$0.01
Margins
Gross margin is 39.93%, with operating margin of -443.63%, and net profit margin of -354.85%.
- Gross Margin
- 39.93%
- Operating Margin
- -443.63%
- Pretax Margin
- -460.34%
- Net Profit Margin
- -354.85%
- EBITDA Margin
- -434.49%
- EBIT Margin
- -443.78%
Analyst Forecast
The average price target for BioLargo is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -70.95%
- EPS Growth Forecast
- -257.36%
Scores
- Smart Score
- ―
- AI Score
- 44

